Genmab — December 2016
-
-
Myeloma Canada submits that pERC failed to fully comprehend the gravity of this stage of disease in
patients. At this stage, patients have run out of options for treatment and are close to death. In
particular, the statement “there is a low probability that daratumumab would be cost-effective in this
population compared to other treatments” is at best conjectural and at worst insensitive. -
-
Ja, det kan undre at de kan se så forskelligt på sagerne. Det hele er galt: for dyrt, for lidt effektivitet, for lang infusionstid, ingen bedre livskvalitet. Hvorfor har vi mon ikke hørt noget fra Janssen/Genmab? Kan de stadig være i dialog med de canadiske myndigheder?
-
Genmab meddeler, at der er indsendt registreringsansøgning for daratumumab til behandling af recidiverende/refraktær myelomatose i Japan og opdaterer sine resultatforventninger
-
Der er indsendt registreringsansøgning i Japan for daratumumab til behandling af recidiverende eller refraktær myelomatose
Ansøgningen er baseret på data fra studierne SIRIUS, CASTOR og POLLUX
Genmab modtager milestonebetaling fra Janssen på USD 10 mio. — resultatforventningerne opdateres
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind